Loading clinical trials...

Study to Assess Long-term Effectiveness of Zomacton® and Treatment Adherence in Patients With Growth Hormone Deficiency or Ullrich-Turner Syndrome | Clinical Trials | Clareo Health

TERMINATED

Study to Assess Long-term Effectiveness of Zomacton® and Treatment Adherence in Patients With Growth Hormone Deficiency or Ullrich-Turner Syndrome

A Prospective Non-Interventional Study to Assess Long-term Effectiveness of Zomacton® and Factors Affecting Adherence in Patients With Growth Hormone Deficiency or Growth Retardation Due to Ullrich-Turner Syndrome

NCT03274973•Ferring Pharmaceuticals

View on ClinicalTrials.gov

Summary

Assessment of long-term effectiveness of ZOMACTON in treatment of Growth Hormone Deficiency or growth retardation due to Ullrich-Turner Syndrome and assessment of compliance and adherence, optionally with the aid of an electronic app or patient diary.

Eligibility

Age

0 - 18 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Pediatric patients (\< 18 years) with growth hormone deficiency or growth retardation due to Ullrich-Turner-Syndrome
•Patients already receiving or who have been prescribed Zomacton® de novo according to its German label; the decision to prescribe Zomacton® was made independently from participation and prior to enrollment in this study.
•Patient and their parents (or legal representatives) who are willing and able to provide signed informed consent for use of their personal data.

Exclusion Criteria

•Participation in an interventional clinical study within the last 30 days prior to baseline visit or during the follow-up period

Locations (1)

Klinik fuer Allgemeine Paediatrie der Christian-Albrechts-Universitaet zu Kiel (there might be other sites in this country)

Kiel, Germany

Key Dates

Start Date

May 14, 2018

Primary Completion Date

October 31, 2018

Completion Date

October 31, 2018

Last Updated

December 13, 2018

Enrollment

ACTUAL participants

Conditions

Growth Disorders

Interventions

Zomacton

DRUG

Impact of Iron Deficiency Anemia on Neurobehavioral and Cognitive Development in Children Aged 6 to 24 Months

NCT06662045

Iron-Deficiency AnemiaNeurobehavioral Manifestations+2 more

View study

ACTIVE_NOT_RECRUITINGPHASE2

Growth Hormone in a Patient With a Dominant-Negative GHR Mutation

NCT05382637

Growth Disorders

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 13, 2018Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Study to Assess Long-term Effectiveness of Zomacton® and Treatment Adherence in Patients With Growth Hormone Deficiency or Ullrich-Turner Syndrome

Inclusion Criteria

Exclusion Criteria

Impact of Iron Deficiency Anemia on Neurobehavioral and Cognitive Development in Children Aged 6 to 24 Months

Growth Hormone in a Patient With a Dominant-Negative GHR Mutation

Versartis Trial in Pre-pubertal Japanese Children With Growth Hormone Deficiency (GHD) to Assess Long-Acting Growth Hormone (Somavaratan, VRS-317)

To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ (ECOS Taiwan, Indonesia, Singapore)

Bone Age Assessment in Children Using Ultrasound Compared to Wrist X-ray

Observational Study of Somatropin Treatment in Children